Levothyroxine Sublingual Tablet Stability and Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Levothyroxine sublingual tablets face challenges in maintaining physicochemical stability and optimal dissolution profiles, which affect their efficacy and shelf life.
Innovation Solution
The composition of Levothyroxine sublingual tablets includes Levothyroxine sodium as the active ingredient, combined with specific pharmaceutically acceptable excipients such as mannitol, microcrystalline cellulose, croscarmellose sodium, butylated hydroxyanisole, sodium lauryl sulfate, sodium alginate, and magnesium stearate, prepared using direct compression or granulation methods to ensure stability and rapid absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional tablet formulations are used, then manufacturing is simple, but physicochemical stability and dissolution profiles deteriorate
Solution Approach 1:
The patent employs a composite tablet formulation combining Levothyroxine sodium with specific excipients (mannitol, microcrystalline cellulose, croscarmellose sodium, butylated hydroxyanisole, sodium lauryl sulfate, sodium alginate, and magnesium stearate) in optimized proportions. This composite approach enhances physicochemical stability and dissolution characteristics while maintaining manufacturing feasibility through direct compression or granulation methods.
Solution Approach 2:
The patent optimizes critical formulation parameters including the concentration of Levothyroxine sodium (0.01-3% w/w), the types and amounts of fillers (65-95% w/w), superdisintegrants (1-15% w/w), antioxidants (0.1-3% w/w), surfactants (0.1-3% w/w), stabilizers (1-5% w/w), lubricants (0.1-3% w/w), and solvents (0.1-10% w/w). These parameter optimizations ensure stability and rapid absorption.
2Speed
If sublingual tablet formulation is used, then absorption rate improves, but manufacturing precision requirements increase
Solution Approach 1:
The patent incorporates superdisintegrants (croscarmellose sodium at 1-15% w/w) and surfactants (sodium lauryl sulfate or glyceryl monostearate at 0.1-3% w/w) specifically to enhance local disintegration properties of the sublingual tablet. This ensures rapid breakdown and dissolution in the buccal cavity, achieving fast absorption while maintaining manufacturability through direct compression or granulation.
3Ease of manufacture
If direct compression method is used, then manufacturing simplicity increases, but tablet mechanical strength may decrease
Solution Approach 1:
The patent optimizes the compression parameters and formulation composition to achieve both manufacturing simplicity and adequate mechanical strength. The optimized excipient blend (mannitol, microcrystalline cellulose, croscarmellose sodium, and lubricants) provides sufficient binding and structural integrity for sublingual tablets prepared by direct compression or granulation methods.
Data Source
AI summary
The present invention relates to Levothyroxine compositions and its process for preparation. The present invention specifically relates to a composition of Levothyroxine sublingual tablets comprising Levothyroxine or its pharmaceutically acceptable salts and pharmaceutically acceptable excipients. The present invention more specifically relates to a composition of Levothyroxine sublingual tablets comprising Levothyroxine or its pharmaceutically acceptable salts and pharmaceutically acceptable excipients selected from fillers/diluents, superdisintegrants, antioxidants, surfactants, stabilizers, buffering agents, lubricants and solvents. The present invention also relates to a process for the preparation of Levothyroxine sublingual tablets by direct compression method or granulation method.